Ulcerative Colitis Market Report 2026

The ulcerative colitis market size has grown strongly in recent years. It will grow from $7.87 billion in 2025 to $8.41 billion in 2026 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to improved availability of anti-inflammatory medications, increased diagnosis of inflammatory bowel diseases, expansion of gastroenterology specialty care, rising awareness of autoimmune disorders, advancements in endoscopic diagnostics.

The ulcerative colitis market size is expected to see strong growth in the next few years. It will grow to $11.08 billion in 2030 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to increasing development of next-generation biologics, rising focus on steroid-sparing therapies, expansion of targeted immune modulation treatments, growing integration of digital patient monitoring tools, increasing investments in ibd research and innovation. Major trends in the forecast period include increasing adoption of biologic therapies, rising use of small molecule treatments, growing focus on personalized treatment regimens, expansion of long-term disease management strategies, enhanced emphasis on early and accurate diagnosis.

Rising healthcare expenditure is expected to drive the growth of the ulcerative colitis market going forward. Health expenditure includes all spending on health-related services, family planning, nutrition programs, and emergency care, but excludes costs for drinking water and sanitation. Healthcare spending is increasing due to advancements in medical technology, as new diagnostic tools, treatments, and innovative therapies often come with higher costs, contributing to greater overall healthcare expenditure. Increased healthcare spending can benefit ulcerative colitis patients by improving access to medical care and therapies. For example, in December 2024, according to the Centers for Medicare & Medicaid Services, a US-based agency overseeing Medicare and Medicaid, U.S. healthcare expenditures rose by 7.5% in 2023, reaching $4.9 trillion, or approximately $14,570 per individual. Therefore, rising healthcare expenditures are propelling the growth of the ulcerative colitis market.

Key companies in the ulcerative colitis market are focusing on collaborative initiatives, such as strategic co-development partnerships, to accelerate late-stage biologic development and expand global commercialization capabilities. Strategic co-development partnerships involve agreements where two pharmaceutical companies combine scientific expertise, clinical trial experience, and commercial infrastructure to jointly advance and market a therapeutic candidate, sharing financial and operational responsibilities. For instance, in 2023, Sanofi S.A., a France-based pharmaceutical and healthcare company, formed a strategic partnership with Teva Pharmaceuticals, a US-based subsidiary of Teva Pharmaceutical Industries Ltd., to co-develop and commercialize TEV’574, a Phase 2b biologic candidate for Crohn’s disease and ulcerative colitis. The agreement included an upfront payment of €0.469 billion (USD 0.5 billion), eligibility for up to €0.94 billion (USD 1 billion) in development and commercialization milestones, and a cost- and profit-sharing arrangement in which Sanofi leads commercialization in North America, Japan, and Asia, while Teva leads in Europe, Israel, and select other regions.

In March 2024, AbbVie Inc., a US-based biopharmaceutical company, acquired Landos Biopharma for an undisclosed amount. Through this acquisition, AbbVie aimed to strengthen and diversify its immunology pipeline by adding a novel, first-in-class oral candidate, expanding its portfolio in inflammatory and autoimmune diseases. Landos Biopharma Inc., a US-based clinical-stage biopharmaceutical company, develops treatments for ulcerative colitis (UC).

Major companies operating in the ulcerative colitis market are AbbVie Inc., AstraZeneca plc, Bausch Health Companies Inc., Eli Lilly and Co., Johnson & Johnson, GlaxoSmithKline plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Allergan plc, Bayer AG, Celgene Corporation, Bristol Myers Squibb Company, Takeda Pharmaceutical Company Limited, Genentech Inc., UCB S.A., Shire plc, Ferring Pharmaceuticals Inc., Salix Pharmaceuticals Inc., Dr. Falk Pharma GmbH, Tillotts Pharma AG, Cosmo Pharmaceuticals.

North America was the largest region in the ulcerative colitis market in 2025. The regions covered in the ulcerative colitis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the ulcerative colitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the ulcerative colitis market by increasing costs of imported biologic drugs, small molecule therapies, pharmaceutical intermediates, syringes, and cold-chain logistics systems. Healthcare providers and pharmaceutical companies in North America and Europe are most affected due to reliance on global biologics supply chains, while Asia-Pacific faces higher production and export costs. These tariffs are contributing to higher treatment expenses and reimbursement pressures. At the same time, they are supporting local biologics manufacturing, regional drug development initiatives, and expanded domestic pharmaceutical capabilities.

The ulcerative colitis market research report is one of a series of new reports that provides ulcerative colitis market statistics, including ulcerative colitis industry global market size, regional shares, competitors with a ulcerative colitis market share, detailed ulcerative colitis market segments, market trends and opportunities, and any further data you may need to thrive in the ulcerative colitis industry. This ulcerative colitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Ulcerative colitis is a chronic inflammatory bowel disease (IBD) classified as an autoimmune disorder, where the immune system attacks healthy tissue in the large intestine, causing inflammation in its superficial layer. Symptoms include diarrhea, weight loss, abdominal cramping, anemia, and the presence of blood or pus in bowel movements, among others.

The main categories of drugs for ulcerative colitis include anti-inflammatory drugs, anti-TNF biologics, immunosuppressants, calcineurin inhibitors, and others. Anti-inflammatory drugs are substances that reduce inflammation (redness, swelling, and pain) in the body. They are prescribed for conditions such as ulcerative proctitis, proctosigmoiditis, left-sided colitis, pancolitis or universal colitis, and fulminant colitis, with molecule types including biologics and small molecules, which can be administered orally or via injection. These drugs are used by various end-users, including hospital pharmacies, retail pharmacies, drug stores, and others.

The ulcerative colitis market consists of sales of aminosalicylates and corticosteroids. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.